Skip to content

BillionToOne

US · BLLN #2109 by market cap Listed 2025
95.75 -4.19 -4.19%
Live - 5344 symbols - heartbeat 80s ago · 2026-10-08 08:12
Pre-market 95.75 0.00%
After-hours 95.75 0.00%
Market cap
4.52B
P/B
8.42
EPS
0.06
Reader sentiment Are you bullish or bearish on BLLN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 8.87 Expensive vs history 76th percentile
5-year average -0.33 · #32 of 40 in Diagnostics & Research
P/E ratio 142.29 In line with history 54th percentile
5-year average 175.49 · forward 104.02 · #18 of 19 in Diagnostics & Research
P/S ratio 11.98 In line with history 36th percentile
5-year average 13.74 · forward 9.41 · #35 of 43 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
BillionToOne (BLLN) 4.52B 135.05 8.42 0.00%
Thermo Fisher Scientific (TMO) 244.79B 35.63 4.65 0.27%
Danaher (DHR) 153.60B 38.81 2.92 0.66%
Natera (NTRA) 57.02B -293.01 31.30 0.00%
Agilent Technologies (A) 47.67B 33.35 6.47 0.60%
Waters (WAT) 42.84B 110.38 2.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value86.36 Economic moatNone UncertaintyHigh

Trading 9.8% above Morningstar's fair value estimate.

Fair value

BillionToOne Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 26% premium over our quantitative fair value estimate of $86.36 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 60.2 lies in the top 10% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.6%, a core component of profitability, falls in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:12:47 · For reference only, not investment advice and not tailored to your situation.